Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Maffezzini

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Clinical Genitourinary Cancer|January 8, 2014
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancerAndrea Necchi, Luigi Mariani, Patrizia Giannatempo, et al.
Clinical Genitourinary Cancer|March 2, 2015
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral CenterAndrea Necchi, Elena Farè, Salvatore Lo Vullo, et al.
Clinical Genitourinary Cancer|May 3, 2014
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinomaPatrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, et al.
Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.
Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
Tumori|June 18, 2017
Eleven-year management of prostate cancer patients on active surveillance: what have we learned?Cristina Marenghi, Maria Francesca Alvisi, Federica Palorini, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Clinical Genitourinary Cancer|January 8, 2014
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancerAndrea Necchi, Luigi Mariani, Patrizia Giannatempo, et al.
Clinical Genitourinary Cancer|March 2, 2015
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral CenterAndrea Necchi, Elena Farè, Salvatore Lo Vullo, et al.
Clinical Genitourinary Cancer|May 3, 2014
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinomaPatrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, et al.
Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.
Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
Tumori|June 18, 2017
Eleven-year management of prostate cancer patients on active surveillance: what have we learned?Cristina Marenghi, Maria Francesca Alvisi, Federica Palorini, et al.
Pageof 8